| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
156 |
| issn |
1570-159X |
| issueIdentifier |
3 |
| pageRange |
149-156 |
| publicationName |
Current Neuropharmacology |
| startingPage |
149 |
| bibliographicCitation |
Kenakin T. Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs. Curr Neuropharmacol. 2007 Sep;5(3):149–56. PMID: 19305797; PMCID: PMC2656818. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f721be2b004dc2ca95c209ab2a6ef49f |
| date |
2007-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/19305797
https://pubmed.ncbi.nlm.nih.gov/PMC2656818
https://doi.org/10.2174/157015907781695973 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33799
https://portal.issn.org/resource/ISSN/1570-159X |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65015
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_034e8f4842428b1bd8db28af167d55d8
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3689 |